Clinical Trials in China / NCT06002711
Recruiting
Observational
Multi-Dimensional MRI Spatial Heterogeneity Analysis for Predicting Key Genes and Prognosis of High-Grade Gliomas: A Multi-Center Study
NCT06002711 · tracked via the Priya Life Science China tracker
Condition(s) studied
High-grade Glioma
Investigational drug(s) / intervention(s)
MR scanning; Clinical data collection
MR scanning; Clinical data collection: Multi-dimensional spatial heterogeneity analysis of MRI
Study summary
1. To retrospectively explore the feasibility of multi-dimensional heterogeneity imaging features of MRI in predicting the status of key gene mutations in high-grade gliomas;
2. To prospectively explore the correlation between multi-dimensional heterogeneous MRI image features and prognosis of high-grade glioma patients.
Eligibility
Inclusion Criteria:
Retrospective Study:
1. Participants aged 18 to 70 years, of any gender.
2. Confirmed postoperative pathology of adult diffuse glioma (WHO Grade III-IV).
3. Standard MR contrast-enhanced imaging performed within 10 days before surgery.
4. No history of prior radiotherapy or chemotherapy before surgery.
5. Absence of concurrent significant comorbidities or other tumors.
6. Presence of molecular testing results (including IDH, MGMT, 1p19q, TERT, CDKN2A/B, BRAF).
7. Availability of comprehensive clinical and follow-up data.
Prospective Study:
1. Participants aged 18 to 70 years, of any gender.
2. Clinically suspected to have high-grade gliomas preoperatively, with final pathology confirming high-grade gliomas.
3. Stable vital signs and capable of cooperating for a 40-minute MR scan.
4. Absence of significant underlying medical conditions or history of other tumors.
5. Documentation of informed consent through a signed consent form.
Exclusion Criteria:
Retrospective Study:
1. MRI images with artifacts or presence of intratumoral hemorrhage.
2. Incomplete clinical data available.
Prospective Study:
1. Individuals with claustrophobia or other reasons unable to undergo MRI scans.
2. History of allergic reactions to MRI contrast agents.
3. Inappropriate for prolonged MRI scans due to other reasons.
Primary outcome measure(s)
- Survival prediction model — 2025.06-2026.09
Survival prediction efficiency of the included samples - Time-depended ROC curve — 2025.06-2026.09
A time-dependent ROC curve which will be drawn according to the survival analysis.
Trial sites (2)
| Facility | City | Region | Status |
|---|---|---|---|
| Department of Radiology, Renji Hospital School of Medicine, Shanghai Jiao Tong University | Shanghai | Select A State Or Province | Recruiting |
| Department of Radiology, Renji hospital, School of Medicine, Shanghai Jiao Tong University | Shanghai | Shanghai Municipality | Active Not Recruiting |
More RenJi Hospital trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06002711 on ClinicalTrials.gov ↗ ← All trials in China